These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32245167)

  • 1. Composition and Orientation of the Core Region of Novel HIV-1 Entry Inhibitors Influences Metabolic Stability.
    Karadsheh R; Meuser ME; Cocklin S
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32245167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition.
    Lai YT
    Viruses; 2021 May; 13(5):. PubMed ID: 34066522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fostemsavir: First Approval.
    Markham A
    Drugs; 2020 Sep; 80(14):1485-1490. PubMed ID: 32852743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic Characterization of Novel HIV-1 Entry Inhibitors: Discovery of a Relationship between Off-Rate and Potency.
    Meuser ME; Murphy MB; Rashad AA; Cocklin S
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30081466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
    Wang T; Ueda Y; Zhang Z; Yin Z; Matiskella J; Pearce BC; Yang Z; Zheng M; Parker DD; Yamanaka GA; Gong YF; Ho HT; Colonno RJ; Langley DR; Lin PF; Meanwell NA; Kadow JF
    J Med Chem; 2018 Jul; 61(14):6308-6327. PubMed ID: 29920093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
    Meanwell NA; Krystal MR; Nowicka-Sans B; Langley DR; Conlon DA; Eastgate MD; Grasela DM; Timmins P; Wang T; Kadow JF
    J Med Chem; 2018 Jan; 61(1):62-80. PubMed ID: 29271653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab.
    Gartland M; Stewart E; Zhou N; Li Z; Rose R; Beloor J; Clark A; Tenorio AR; Krystal M
    Antiviral Res; 2024 Aug; 228():105957. PubMed ID: 38971430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies?
    Idemyor V
    HIV Clin Trials; 2005; 6(5):272-7. PubMed ID: 16306033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry.
    Lai YT; Wang T; O'Dell S; Louder MK; Schön A; Cheung CSF; Chuang GY; Druz A; Lin B; McKee K; Peng D; Yang Y; Zhang B; Herschhorn A; Sodroski J; Bailer RT; Doria-Rose NA; Mascola JR; Langley DR; Kwong PD
    Nat Commun; 2019 Jan; 10(1):47. PubMed ID: 30604750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients.
    Saladini F; Giannini A; Giammarino F; Maggiolo F; Vichi F; Corbelli GM; Galli A; Bigoloni A; Poli A; Santoro MM; Zazzi M; Castagna A
    J Antimicrob Chemother; 2020 Sep; 75(9):2547-2553. PubMed ID: 32464638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
    Zhang Y; Chapman JH; Ulcay A; Sutton RE
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay.
    Gartland M; Zhou N; Stewart E; Pierce A; Clark A; Ackerman P; Llamoso C; Lataillade M; Krystal M
    J Antimicrob Chemother; 2021 Feb; 76(3):648-652. PubMed ID: 33241285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Antiretroviral Agents.
    Cambou MC; Landovitz RJ
    Curr HIV/AIDS Rep; 2020 Apr; 17(2):118-124. PubMed ID: 32052271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations.
    Alencar CS; Nishiya AS; Ferreira S; Giret MT; Diaz RS; Sabino EC
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1267-71. PubMed ID: 20977300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection.
    Chahine EB
    Am J Health Syst Pharm; 2021 Feb; 78(5):376-388. PubMed ID: 33547469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Field-Based Affinity Optimization of a Novel Azabicyclohexane Scaffold HIV-1 Entry Inhibitor.
    Meuser ME; Rashad AA; Ozorowski G; Dick A; Ward AB; Cocklin S
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31013646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.